RFA-DK-27-126: Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning Community (KUH-FAMILY) (U24 Clinical Trials Not Allowed)

RFA-DK-27-126: Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning Community (KUH-FAMILY) (U24 Clinical Trials Not Allowed)

Key details

What this opportunity is and why it matters

This is an NIH/NIDDK grant opportunity under the kidney, urologic, and hematologic disease portfolio that is specifically framed as a coordinated community-building and learning infrastructure action rather than a standard independent lab grant. The KUH-FAMILY initiative is intended to pull together expertise across institutions to accelerate translational progress where disease complexity crosses traditional boundaries and where isolated projects risk duplication or fragmentation.

The title is long and bureaucratic for a reason: it signals a structural shift in how NIDDK wants to seed progress. In this mechanism, the value is not only in one scientific idea but in how multiple funded actors share standards, datasets, infrastructure, and cross-site learning habits in a way that can produce faster, repeatable gains over time.

The opportunity is centered around the U24 cooperative-agreement format, which matters for applicants. A U24 is usually a coordinating center model: the awardee is expected to create or lead shared mechanisms, produce common resources, and make operational processes that are reusable beyond one laboratory or project period. In other words, the expected success metrics are often process reliability, coordination value, and community-level impact, not just project-level novelty.

The page data indicates this is positioned as forecasted, and that the estimated application window is now active in the 2026 planning cycle with a deadline in July 2026. That makes this an excellent opportunity for teams that are already engaged in kidney/urologic/hematologic translational research and want to move from isolated projects to a national collaboration model.

Why this fits the 2026/2027 cycle

The listing ties this call to the 2026/2027 cycle with clear date stamps and indicates it is in the active application planning window. For funding calendars, that matters in three ways:

First, it is likely to be relevant for teams assembling applications this quarter. Second, it is a strategic fit for institutions that already maintain data infrastructure and cross-site governance. Third, because the forecast is still visible and dates are not too far out relative to award planning, teams can still influence scope and partnership design before submission.

Forecasted or pre-provisional entries can change before final release. You should treat the posted facts as current planning signals and re-check the official page before final submission. The date window suggests this is not historical archive material; it is an active opportunity with a near-term pipeline if your institution can complete compliance in time.

Who should consider applying

This is not an individual fellowship or trainee grant. It is best for organizations capable of coordinating shared research functions. The strongest applicants are usually teams that can do all of the following at scale:

1. Establish common standards and governance.
2. Maintain secure, compliant research operations.
3. Deliver measurable community-level outputs across centers.

Potentially strong applicant profiles include:

• Academic medical centers with research operations already set up for multi-site activities.
• Institutional and public entities with existing leadership for translational kidney, urologic, or hematologic projects.
• Nonprofits and eligible for-profit organizations that can support an operational center role.
• Small businesses with a clearly defined translational role and administrative readiness for federal submission.

The listed eligibility categories are broad and include public, educational, governmental, nonprofit, and private organizations with constraints consistent with standard NIH notices. If your organization is not sure, treat it as a compliance exercise: verify institutional status, legal identity, and award eligibility against the full notice before drafting a final narrative.

Because this is a U24, the quality of leadership and coordination may matter more than the novelty of one standalone experiment. In practice, applicants are often judged on whether they can serve as a credible nexus for others: can they define standards, support shared implementation, and sustain communication and technical workflow across teams.

Eligibility details to interpret carefully

The listing includes a broad set of eligible applicants and does specifically mention that this is a U.S.-focused award path with constraints around direct recipients. It also indicates foreign organizations are not eligible as direct awardees, though they may appear in subaward or collaboration roles if allowed by NIH rules.

From a planning perspective:

• Confirm whether your organization is eligible under the specific applicant classes on the official opportunity page.
• If your plan includes foreign partners, map them as collaborators rather than awardee lead roles.
• If you are a hospital or university partner, confirm that official registrant identities and signatures can be completed on time.
• If you are a small business, ensure the proposed role and deliverables are aligned with a coordinating or technical support function.

Potential ambiguity around the term “eligible applicants” is common in forecast pages. NIH RFAs tend to present broad categories, and the final NOFO may narrow interpretation in examples, definitions, and allowed roles. The safest path is to anchor your decision to the direct language on the latest official source just before submission.

What the opportunity likely funds and expects

The KUH-FAMILY framing points to a structured coordination platform across kidney, urologic, and hematologic research. The expected value to NIDDK likely comes from five capabilities that an isolated proposal often fails to provide on its own:

• A shared scientific roadmap across participating centers.
• Reproducible data-sharing and governance structure.
• Training or technical support mechanisms that improve participation quality.
• Translational alignment between preclinical insight and near-term clinical applicability.
• A sustainable coordination architecture that continues to serve subsequent cohorts of investigators.

The title’s term “AdvanceMent” emphasizes deliberate iteration: not a one-time event, but a setup where teams continually incorporate what works and retire what does not. That typically favors teams with evidence of operational discipline and implementation readiness.

A useful perspective is to think of this as infrastructure grant logic mixed with scientific scope governance. The funding may not primarily reward the largest number of novel molecular hypotheses; it may reward design quality in how ideas are shared, compared, and converted into reproducible multi-site outputs. For many institutions, this is closer to building a public-good layer than writing a standard R01 package.

Timeline, planning, and submission flow

The planning clock is straightforward but strict. The currently listed dates show a short interval between expected open date and application due date, so preparation should be treated as near-term work.

Phase 1: Calendar lock and responsibility map

Immediately set a concrete internal deadline structure around the July 1, 2026 due date. Since federal applications can fail for administrative reasons, every action should have a buffer:

• T-90 days: confirm institution-level eligibility and lead role.
• T-60 days: draft concept note and partnership letters.
• T-35 days: complete NIH/Grants.gov registration requirements and test account access.
• T-21 days: internal review of budgets, compliance, and attachments.
• T-7 days: final dry run through the electronic package.
• T-2 days: final internal approval and contingency fallback.

This is conservative, but it is realistic for a U24.

Phase 2: Application package preparation

Most applications fail when teams leave institutional readiness until the end. Given this call’s cooperative format, prepare early:

• Project governance and leadership narrative.
• Consortium architecture and decision workflow.
• Shared data standards and quality controls.
• Roles, timeline, and measurable milestones.
• Risk mitigation plan for partner delays and interoperability issues.

Phase 3: Finalization and pre-submission checks

For grant portal processes, compliance checklists often determine acceptance more than narrative polish. Confirm:

• Authorized official signing authority is valid.
• All required profile and certification steps are active.
• Budget and effort align with role definitions.
• Uploaded files match the required formatting and character limits.

The announcement includes a close/expiration date just after due date, which effectively means you should avoid last-minute resubmission behavior.

Application mechanics and practical checklist

The public page points to Grants.gov as the application path. That implies applicants should be ready for standard federal workflow steps, including registration and data fields required by the portal.

A practical checklist for this specific RFA should include:

• Define the center lead and formalize internal decision rights.
• Draft an explicit scientific coordination plan: what is coordinated, by whom, and how often.
• Prepare a consortium map showing institutional roles and data ownership boundaries.
• Build a submission package timeline with contingency dates.
• Identify and brief all partner organizations before final narrative lock.
• Verify conflict of interest, human-subjects oversight, and data governance requirements early.

Because this is a U24 and is designed for coordination, reviewers and program staff often examine whether teams have credible operating systems, not only strong science words. Treat budget narratives as evidence of operational realism.

Benefits, expectations, and practical caveats

Confirmed by the listing

• The opportunity is centered on kidney, urologic, and hematologic disease domains.
• It is an NIH/NIDDK-driven effort with a cooperative-agreement structure.
• The application is identified as forecasted with a 2026/2027-cycle timeline.
• The notice indicates that direct applications are planned as new applications only.
• The project period is presented as five years in the listing.
• The listing marks clinical trials as not allowed, which is a major design boundary.

Not confirmed and therefore to be treated cautiously

• Exact funding ceiling per award.
• Full program and evaluation criteria details before final NOFO release.
• Exact technical form templates and all attachments for submission.
• Whether any late-stage policy language changes are added before submission.

The official listing page is an active source, but forecasted items can still evolve. If a team waits until the last week, they can miss final clarifications that affect eligibility interpretation or documentation requirements.

For teams that are strong in science but weaker in operations, this call may demand a partner with coordination capacity. If your primary institution can provide governance and data architecture, then science-led collaborators can still contribute materially as technical or clinical leads. If not, this may not be the best fit.

How to increase your chance of being a credible applicant

1. Write a proposal that explains how coordination itself creates outcomes.
2. Show concrete mechanisms for shared outputs, not only separate deliverables.
3. Demonstrate that the lead organization can run a multisite effort with reliable communications and documentation.
4. Provide a measurable framework for progress across the five-year period.
5. Include a realistic partner engagement plan where delays, onboarding, and harmonization are explicitly managed.

Many teams underestimate this opportunity by writing as if it were an individual grant. The stronger strategy is to frame the proposal as a system design problem with a scientific end state and explicit implementation milestones.

Common mistakes to avoid

• Submitting a technically good science idea without a durable coordination architecture.
• Misreading the clinical trial restriction and proposing trial components as the core activity.
• Treating foreign partners as awardee lead roles where they are not eligible.
• Ignoring NIH portal readiness and attempting to complete registrations at the end.
• Understating governance burden: without clear leadership and reporting, U24 reviews often score this weak.
• Assuming forecasted details are final and failing to check final updates before the final package.

The result of those mistakes is usually not rejection for science quality alone; it is rejection because the package does not appear ready for implementation.

Frequently asked questions

Is this a recurring open call or a one-time release?

This appears as a forecasted, cycle-specific opportunity for the 2026/2027 cycle. Its relevance should be evaluated against the latest official posting.

Is there a fixed amount listed in the summary?

No clear total or per-award amount is provided in the currently indexed lines I used for this page. The front matter keeps amount empty so it is not misrepresented.

Can foreign entities apply as lead applicants?

The listing indicates foreign entities are not eligible as direct recipients, but collaboration may be possible in technical roles. Confirm current language in the full announcement.

Does this require clinical trials?

No. The page explicitly states clinical trials are not allowed for this RFA.

Is the timeline realistic for a new applicant?

Yes, but only with a pre-built operational plan. The listed short cycle requires early internal alignment and portal preparation.

Can small businesses apply?

The listed eligibility categories include small businesses as one eligible class in similar NIH notices, but small-business applicants should ensure they can lead or support the required coordinating role.

Official links and what to track every week

Primary source URL:

• https://files.simpler.grants.gov/opportunities/8156f1df-115c-41f0-85d7-a3c9c821361f/attachments/0ef02fbc-2630-4a11-b1ff-d3011dbf2bf4/RFA-DK-27-126-Full-Announcement.html

Supplemental tracking pages to watch for final posting details:

• official Grants.gov opportunity record for RFA-DK-27-126
• NIH funding opportunities and program office notices
• your institutional sponsored-research office updates for NIH submission requirements

Checklist for monitoring:

1. Confirm final status and full announcement publication date.
2. Verify if any administrative supplements or corrections were added.
3. Reconfirm eligibility interpretation with your compliance and grants offices.
4. Re-check contact details and any updates to key personnel names.
5. Download final package files immediately after posting.

Recommended next step before drafting

Use this listing now as a planning anchor. Build a one-page internal concept for the coordinating model first, then map that concept onto the official requirements in the NOFO.

If your institution is ready for a center-style, collaboration-first funding strategy, this call is a strategic fit for 2026 planning. If your operation is still building core administrative and multi-site governance capacity, start there first and return to the full proposal only after the systems work is in place.